Item 8.01. Other Events.

On January 27, 2022, Galecto, Inc. (the "Company") issued a press release announcing the publication of the full results of an investigator-initiated open and randomized trial to evaluate the Company's inhaled galectin-3 inhibitor, GB0139, in hospitalized patients with COVID-19 infection. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits



Exhibit
Number                                    Description

 99.1       Press Release, dated January 27, 2022

  104     Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses